Brief: Passage Bio Announces Positive Interim Clinical Data From First Six Patients With Gm1 Gangliosidosis In Imagine-1 Study

Passage Bio

14/12/2022 12:21

Dec 14 (Reuters) - Passage Bio Inc  PASG.O :
    * PASSAGE BIO ANNOUNCES POSITIVE INTERIM CLINICAL DATA FROM
FIRST
SIX PATIENTS WITH GM1 GANGLIOSIDOSIS IN IMAGINE-1 STUDY
    * PASSAGE BIO INC - INTERIM SAFETY DATA UP TO 20 MONTHS
SHOWED LOW
AND HIGH DOSE OF PBGM01 WERE WELL TOLERATED AND HAD A FAVORABLE
SAFETY PROFILE
    * PASSAGE BIO - COMPLETED DOSING OF ALL PATIENTS IN
DOSE-ASCENDING
PORTION OF STUDY; INITIAL SAFETY & BIOMARKER DATA FROM COHORT 4
EXPECTED BY MID-2023
    * PASSAGE BIO INC - PBGM01 ADMINISTRATION RESULTED IN A
MEANINGFUL
IMPROVEMENT ACROSS DEVELOPMENTAL AREAS IN A SUBSET OF PATIENTS
    * PASSAGE BIO INC - NO TREATMENT-RELATED SERIOUS ADVERSE
EVENTS IN
INTERIM RESULTS FROM COHORTS 1-3 OF THE IMAGINE-1 STUDY

Source text for Eikon:  ID:nGNX29w9jP 
Further company coverage:  PASG.O 
 ((Reuters.Briefs@thomsonreuters.com;))